Access to Rare Indications Act of 2020
Do you support it?
Want to know if it passes?
We'll email you when HR 8467 moves — a committee vote, a floor vote, or a signature. Nothing else.
Free forever · unsubscribe in one click.
Your answer was recorded either way.
Which district are you in?
Your ZIP is all we need to match you to your own representatives — so we can tell you how they voted on HR 8467.
You're tracking HR 8467
We'll email you the moment it moves.
HR 8467 — Access to Rare Indications Act of 2020
Last action — Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
No card. One bill, free forever — alerts when it moves.
-
✓Introduced
-
✓In Committee
-
Died in session
This bill died with 116th Congress. It reached “In Committee” and never advanced before the session ended, so it can no longer move — a new version would have to be reintroduced in the current session.
This bill is no longer active — its legislative session has ended, so there is no live prognosis. It would have to be reintroduced in the current session to move again.
Summary
Prohibits coverage exclusions or limitations under the Medicare prescription drug benefit, Medicaid, or private health insurance of certain drugs that are used to treat rare diseases or conditions (i.e., diseases or conditions that affect 200,000 or fewer individuals and that are supported by the National Institutes of Health Rare Diseases Clinical Research Network).
Bill Text
We don't have the full text on file for this bill yet.
Read HR 8467 on the official United States source →Action History
-
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
-
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
-
Introduced in House
Sponsors
- Mike Thompson · Primary
Sponsorship breakdown
Export CSV (upgrade) →1 sponsors · 0 co-sponsors · 546 not signed on
Sponsors (1)
Co-sponsors (0)
None.
Not signed on (546)
546 members have not signed on to this bill.
Show all 546 →"Not signed on" means a member has not sponsored or co-sponsored this bill — it does not imply opposition. Members flagged Voted No have a recorded No vote on this bill.
Subjects
Frequently asked questions
- What does HR 8467 do?
- Prohibits coverage exclusions or limitations under the Medicare prescription drug benefit, Medicaid, or private health insurance of certain drugs that are used to treat rare diseases or conditions (i.e., diseases or conditions that affect 200,000 or fewer individuals and that are supported by the National Institutes of Health Rare Diseases Clinical Research Network).
- Who sponsors HR 8467?
- HR 8467 is sponsored by Mike Thompson (D).
- What is the current status of HR 8467?
- This bill died with 116th Congress. It reached “In Committee” and never advanced before the session ended, so it can no longer move — a new version would have to be reintroduced in the current session.
- Where can I track HR 8467?
- Track HR 8467 free on One Click Politics — get push/email alerts when it moves.
Make your voice heard on HR 8467
Find the representatives who decide this bill and tell them where you stand — for yourself, or mobilize your whole list in one click with One Click Politics advocacy software.
Stay ahead of HR 8467
Last checked for changes about 12 hours ago · updated continuously
One Click Politics tracks every bill in Congress and all 50 states.
Track this bill →